View in EDS HTML Full Text PDF Full Text

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Authors: Wagemann O; Department of Neurology, Washington University School of Medicine, St Louis, Missouri.; Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany., Liu H; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Wang G; Department of Biostatistics, Washington University in St Louis, St Louis, Missouri., Shi X; Department of Biostatistics, Washington University in St Louis, St Louis, Missouri., Bittner T; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Scelsi MA; F. Hoffmann-La Roche Products Ltd, Welwyn Garden City, United Kingdom., Farlow MR; Department of Neurology, Indiana University School of Medicine, Indianapolis., Clifford DB; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Supnet-Bell C; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Santacruz AM; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Aschenbrenner AJ; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Hassenstab JJ; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Benzinger TLS; Department of Radiology, Washington University in St Louis, St Louis, Missouri., Gordon BA; Department of Radiology, Washington University in St Louis, St Louis, Missouri., Coalier KA; IQVIA, Durham, North Carolina., Cruchaga C; Department of Psychiatry, Washington University in St Louis, St Louis, Missouri., Ibanez L; Department of Neurology, Washington University School of Medicine, St Louis, Missouri.; Department of Psychiatry, Washington University in St Louis, St Louis, Missouri., Perrin RJ; Department of Neurology, Washington University School of Medicine, St Louis, Missouri.; Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri., Xiong C; Department of Biostatistics, Washington University in St Louis, St Louis, Missouri., Li Y; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Morris JC; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Lah JJ; Department of Neurology, School of Medicine Emory University, Atlanta, Georgia., Berman SB; Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania., Roberson ED; Department of Neurology, University of Alabama at Birmingham, Birmingham., van Dyck CH; Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, Connecticut., Galasko D; Department of Neurology, University of California, San Diego., Gauthier S; Department of Neurology & Psychiatry, McGill University, Montréal, Québec, Canada., Hsiung GR; Department of Neurology, University of British Columbia, Vancouver, British Columbia, Canada., Brooks WS; Neuroscience Research Australia, Sydney, New South Wales, Australia.; School of Clinical Medicine, University of New South Wales, Randwick, New South Wales, Australia., Pariente J; Department of Neurology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Mummery CJ; Dementia Research Centre, Institute of Neurology, University College London, London, United Kingdom., Day GS; Department of Neurology, Mayo Clinic Florida, Jacksonville., Ringman JM; Department of Neurology, University of Southern California, Los Angeles., Mendez PC; Fundación Para la Lucha Contra las Enfermedades Neurológicas de la Infancia (FLENI), Buenos Aires, Argentina., St George-Hyslop P; Department of Neurology, Columbia University, New York, New York., Fox NC; Dementia Research Centre, Institute of Neurology, University College London, London, United Kingdom., Suzuki K; National Defense Medical College, Saitama, Japan., Okhravi HR; Department of Geriatrics, Eastern Virginia Medical School, Norfolk., Chhatwal J; Department of Neurology, Massachusetts General and Brigham & Women's Hospitals, Harvard Medical School, Boston., Levin J; Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Jucker M; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Sims JR; Eli Lilly and Company, Indianapolis, Indiana., Holdridge KC; Eli Lilly and Company, Indianapolis, Indiana., Proctor NK; Eli Lilly and Company, Indianapolis, Indiana., Yaari R; Eli Lilly and Company, Indianapolis, Indiana., Andersen SW; Eli Lilly and Company, Indianapolis, Indiana., Mancini M; Eli Lilly and Company, Indianapolis, Indiana., Llibre-Guerra J; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., Bateman RJ; Department of Neurology, Washington University School of Medicine, St Louis, Missouri., McDade E; Department of Neurology, Washington University School of Medicine, St Louis, Missouri.
Corporate Authors: Dominantly Inherited Alzheimer Network–Trials Unit
Source: JAMA neurology [JAMA Neurol] 2024 Jun 01; Vol. 81 (6), pp. 582-593.
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2168-6157
DOI:10.1001/jamaneurol.2024.0991